$PLSH
Panacea Life Sciences Holdings Inc Stock $plsh

$plsh Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224017858 Filed on May 06, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue		$1.056M	$960.5K
YoY Change		55.94%	195.73%
Cost Of Revenue		$390.3K	$1.941M
YoY Change		-13.63%	26.59%
Gross Profit		$666.2K	-$981.0K
YoY Change		195.27%	-18.86%
Gross Profit Margin		63.06%	-102.13%
Selling, General & Admin		$249.0K	$787.1K
YoY Change		0.66%	372.34%
% of Gross Profit		37.38%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$383.5K	$443.7K
YoY Change		-9.24%	-0.25%
% of Gross Profit		57.57%
Operating Expenses		$1.724M	$787.1K
YoY Change		13.72%	372.34%
Operating Profit		-$1.057M	-$1.768M
YoY Change		-18.03%	28.53%
Interest Expense		$429.7K	-$475.7K
YoY Change		13.02%	22.87%
% of Operating Profit
Other Income/Expense, Net		-$388.7K	$35.02K
YoY Change		-22.46%	-39.67%
Pretax Income		-$1.446M	-$2.209M
YoY Change		-19.27%	29.57%
Income Tax			$0.00
% Of Pretax Income
Net Earnings		-$1.446M	-$2.209M
YoY Change		-19.27%	29.57%
Net Earnings / Revenue		-136.88%	-229.95%
Basic Earnings Per Share		-$0.09
Diluted Earnings Per Share		-$0.09	-$0.13
COMMON SHARES
Basic Shares Outstanding	17.65M shares	16.49M shares	17.65M shares
Diluted Shares Outstanding		16.49M shares

Balance Sheet

Concept	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$117.2K	$115.9K
YoY Change	-88.27%	-89.6%
Cash & Equivalents	$107.6K	$100.9K
Short-Term Investments	$9.500K	$14.93K
Other Short-Term Assets	$192.1K	$263.0K
YoY Change	144.6%	132.54%
Inventory	$4.063M	$4.014M
Prepaid Expenses
Receivables	$270.9K	$264.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$4.643M	$4.656M
YoY Change	-21.92%	-27.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.070M	$6.448M
YoY Change	-16.5%	-16.0%
Goodwill	$3.014M	$3.014M
YoY Change	37.72%	37.72%
Intangibles	$3.014M	$3.014M
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$12.77M	$13.33M
YoY Change	1.27%	1.68%
TOTAL ASSETS
Total Short-Term Assets	$4.643M	$4.656M
Total Long-Term Assets	$12.77M	$13.33M
Total Assets	$17.41M	$17.98M
YoY Change	-6.17%	-7.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.178M	$4.630M
YoY Change	68.88%	73.65%
Accrued Expenses	$3.055M	$2.914M
YoY Change	38.36%	39.4%
Deferred Revenue
YoY Change
Short-Term Debt	$12.16M	$11.90M
YoY Change	14.53%	15.38%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$20.39M	$19.45M
YoY Change	28.33%	29.02%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.573M	$3.573M
YoY Change	0.0%	0.0%
Total Long-Term Liabilities	$3.573M	$3.573M
YoY Change	0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.39M	$19.45M
Total Long-Term Liabilities	$3.573M	$3.573M
Total Liabilities	$27.04M	$26.27M
YoY Change	20.92%	21.45%
SHAREHOLDERS EQUITY
Retained Earnings	-$35.37M	-$33.92M
YoY Change	27.69%	30.98%
Common Stock	$1.832K	$1.765K
YoY Change	18.12%	17.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$9.623M	-$8.291M
YoY Change
Total Liabilities & Shareholders Equity	$17.41M	$17.98M
YoY Change	-6.17%	-7.73%

Cashflow Statement

Concept	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$1.446M	-$2.209M
YoY Change	-19.27%	29.57%
Depreciation, Depletion And Amortization	$383.5K	$443.7K
YoY Change	-9.24%	-0.25%
Cash From Operating Activities	-$357.1K	$1.580K
YoY Change	13.78%	-100.3%
INVESTING ACTIVITIES
Capital Expenditures	$5.000K	$17.90K
YoY Change	-67.15%	-81.89%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change
Cash From Investing Activities	-$5.000K	-$17.90K
YoY Change	-67.15%	-81.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$368.8K	115.8K
YoY Change	-6.71%	-80.45%
NET CHANGE
Cash From Operating Activities	-$357.1K	1.580K
Cash From Investing Activities	-$5.000K	-17.90K
Cash From Financing Activities	$368.8K	115.8K
Net Change In Cash	$6.721K	99.44K
YoY Change	-89.86%	-433.24%
FREE CASH FLOW
Cash From Operating Activities	-$357.1K	$1.580K
Capital Expenditures	$5.000K	$17.90K
Free Cash Flow	-$362.1K	-$16.32K
YoY Change	10.03%	-97.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	666165	usd
CY2024Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1474475	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	249038	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	1723513	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1057348	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	429672	usd
CY2024Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	5053	usd
CY2024Q1	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	36269	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-388726	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1446074	usd
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001552189
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2024Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable		usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss		usd
CY2024Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet		usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet		usd
CY2024Q1	PLSH	Employer Retention Credit EmployerRetentionCredit		usd
CY2023Q1	PLSH	Employer Retention Credit EmployerRetentionCredit		usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss		usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	PLSH	Conversion Of Note Payable To Common Stock ConversionOfNotePayableToCommonStock		usd
CY2023Q4	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueOutstanding		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q1	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueOutstanding		usd
CY2024Q1	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Vested And Exercisable In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionVestedAndExercisableInPeriodWeightedAverageIntrinsicValue		usd
CY2023Q4	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueOutstanding		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2024Q1	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2024Q1	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Exercised In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice
CY2024Q1	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueOutstanding		usd
CY2024Q1	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Vested And Exercisable In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionVestedAndExercisableInPeriodWeightedAverageIntrinsicValue		usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-38190
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	Panacea Life Sciences Holdings, Inc.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-1085858
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5910 S University Blvd
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	C18-193
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Greenwood Village
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80121
CY2024Q1	dei	City Area Code CityAreaCode	800
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	985-0515
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17645352	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	107643	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100922	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	270851	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	263970	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	4062827	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	4013525	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	9504	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	14933	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	192133	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	263003	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	4642958	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4656353	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3685567	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3864591	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6069570	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6448068	usd
CY2024Q1	us-gaap	Goodwill Goodwill	3014450	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3014450	usd
CY2024Q1	us-gaap	Assets Assets	17412545	usd
CY2023Q4	us-gaap	Assets Assets	17983462	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5178214	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4629591	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3055134	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2913781	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	115000	usd
CY2024Q1	PLSH	Paycheck Protection Loan PaycheckProtectionLoan	99100	usd
CY2023Q4	PLSH	Paycheck Protection Loan PaycheckProtectionLoan	99100	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	20391818	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19448031	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3070391	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3254021	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3572864	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3572864	usd
CY2024Q1	us-gaap	Liabilities Liabilities	27035073	usd
CY2023Q4	us-gaap	Liabilities Liabilities	26274916	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	650000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	650000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18311352	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18311352	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17645352	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17645352	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	1832	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1765	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	25743375	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	25628442	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35368972	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33922898	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-9622528	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-8291454	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17412545	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17983462	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1056447	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	677481	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	390282	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	451872	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	225609	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1258159	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	257413	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	1515572	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1289963	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	380157	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-182255	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-376	usd
CY2023Q1	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	60332	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	748	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-501332	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1791295	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1446074	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1791295	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16492589	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16492589	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14965317	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14965317	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-8291454	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	115000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1446074	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-9622528	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2144544	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2144544	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	135000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1791295	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3800839	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3800839	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1446074	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1791295	usd
CY2024Q1	us-gaap	Depreciation Depreciation	383498	usd
CY2023Q1	us-gaap	Depreciation Depreciation	422554	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-376	usd
CY2024Q1	PLSH	Marketable Securities Unrealized Gain Losses MarketableSecuritiesUnrealizedGainLosses	-5053	usd
CY2023Q1	PLSH	Marketable Securities Unrealized Gain Losses MarketableSecuritiesUnrealizedGainLosses	-182255	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	38329	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6881	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	68660	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	49302	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-353662	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-70870	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-34552	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	548623	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	400059	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	136747	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	114693	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-357090	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-313851	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15220	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15220	usd
CY2024Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5831	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	135000	usd
CY2024Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	74000	usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	65000	usd
CY2024Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	448642	usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	595352	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	368811	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	395352	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6721	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	66281	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	100922	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6951	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	107643	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	73232	usd
CY2024Q1	PLSH	Conversion Of Note Payable To Common Stock ConversionOfNotePayableToCommonStock	-115000	usd
CY2024Q1	us-gaap	Other General Expense OtherGeneralExpense	134000000000	usd
CY2024Q1	us-gaap	Area Of Land AreaOfLand	51000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35369000	usd
CY2024Q1	us-gaap	Cash Cash	117000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zbZvznAZejra" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zq1fDlkjsDGb">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Unaudited Condensed Consolidated Financial Statements have been prepared in conformity with US GAAP and required management of the Company to make estimates and assumptions in preparation of these statements. Actual results may differ significantly from those estimates. Significant estimates made by management include but are not limited to the useful life of property and equipment, incremental borrowing rate used in the calculation of right of use asset and lease liability, reserves for inventory, allowance for doubtful accounts, revenue allocations, valuation allowance on deferred tax assets, assumptions used in assessing impairment of long-term assets, assumptions used in the calculation of net realizable value of inventory and fair value of non-cash equity transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	50000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2024Q1	us-gaap	Investment Owned Balance Shares InvestmentOwnedBalanceShares	79200	shares
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	9504	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	14933	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	14933	usd
CY2024Q1	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	376	usd
CY2024Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	5053	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	9504	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3014450	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3014450	usd
CY2024Q1	PLSH	Customer Advances Payments CustomerAdvancesPayments	400955	usd
CY2023Q4	PLSH	Customer Advances Payments CustomerAdvancesPayments	349705	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12277629	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6632816	shares
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12277629	shares
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	349705	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	368065	usd
CY2024Q1	PLSH	Payments Received For Unearned Revenue PaymentsReceivedForUnearnedRevenue	143469	usd
CY2023	PLSH	Payments Received For Unearned Revenue PaymentsReceivedForUnearnedRevenue	156298	usd
CY2024Q1	PLSH	Revenue Earned Amount RevenueEarnedAmount	92219	usd
CY2023	PLSH	Revenue Earned Amount RevenueEarnedAmount	174658	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	400955	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	349705	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6632816	shares
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13688915	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13683915	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7619345	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7235847	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6069570	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6448068	usd
CY2024Q1	us-gaap	Depreciation Depreciation	383498	usd
CY2023Q1	us-gaap	Depreciation Depreciation	422554	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3070391	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3254021	usd
CY2024Q1	PLSH	Shortterm Portion Of Operating Lease Liability ShorttermPortionOfOperatingLeaseLiability	722930	usd
CY2023Q4	PLSH	Shortterm Portion Of Operating Lease Liability ShorttermPortionOfOperatingLeaseLiability	718675	usd
CY2024Q1	PLSH	Unpaid Balance UnpaidBalance	2300802	usd
CY2024Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	892377	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	850362	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1785949	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1870978	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1358063	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1262674	usd
CY2024Q1	PLSH	Packaging Supplies PackagingSupplies	26438	usd
CY2023Q4	PLSH	Packaging Supplies PackagingSupplies	29511	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	4062827	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	4013525	usd
CY2024Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2030-12-31
CY2024Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2030-12-31
CY2024Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3685567	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3864591	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3793321	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3972696	usd
CY2023Q4	PLSH	Unpaid Balance UnpaidBalance	2185758	usd
CY2024Q1	PLSH	Operating Leases Liability Current OperatingLeasesLiabilityCurrent	3023732	usd
CY2023Q4	PLSH	Operating Leases Liability Current OperatingLeasesLiabilityCurrent	2904433	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y9M3D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y11M15D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.030	pure
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	437752	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	114693	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	621570	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	830307	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	764830	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	474122	usd
CY2024Q1	PLSH	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree	1451002	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4141831	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	348510	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3793321	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3572864	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3572864	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	650000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	551854	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.84
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y2M4D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	15000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	536854	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.88
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y10M28D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	196491	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.88
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y10M28D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1104243	shares
CY2023Q4	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Number Of Share ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare	1.70
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P3Y1M28D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	25670	shares
CY2024Q1	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Forfeited Or Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice	5.60
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1078573	shares
CY2024Q1	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Number Of Share ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare	1.70
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y11M1D
CY2024Q1	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	1078573	shares
CY2024Q1	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice	1.70
CY2024Q1	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm	P2Y11M1D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	107993	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	107993	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001

Files In Submission

Name	View Source	Status
0001493152-24-017858-index-headers.html	Edgar Link	pending
0001493152-24-017858-index.html	Edgar Link	pending
0001493152-24-017858.txt	Edgar Link	pending
0001493152-24-017858-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
plsh-20240331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
plsh-20240331_cal.xml	Edgar Link	unprocessable
plsh-20240331_def.xml	Edgar Link	unprocessable
plsh-20240331_lab.xml	Edgar Link	unprocessable
plsh-20240331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLSH
Panacea Life Sciences Holdings Inc Stock $plsh

2024 Q2 Form 10-Q Financial Statement

#000149315224017858 Filed on May 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLSH Panacea Life Sciences Holdings Inc Stock $plsh

2024 Q2 Form 10-Q Financial Statement

#000149315224017858 Filed on May 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLSH
Panacea Life Sciences Holdings Inc Stock $plsh